EUCTR2010-023889-52-SE进行中（未招募）不适用
Effects of Clindamycin and Ciprofloxacin administration on the emergence, prevalence and persistence of antibiotic-resistant bacteria in humans
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed an informed consent prior to any study related procedure.
- •2. Female or male subject, 18 to 40 years of age, inclusive. To avoid pregnancy, and the risk of not completing the study, females must use highly effective contraceptive methods (see section 7.5 for details).
- •3. Body mass index (weight [kg]/height2 [m]2) between 18 and 30 kg/m2 (inclusive), and body weight, not less than 45 kg.
- •4. Normal findings in the medical history and physical examination, unless the investigator consider an abnormality to be clinically irrelevant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of or current clinically significant medical illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results.
- •2. History of multiple yearly incidents of infectious diseases treated with antibiotics (e.g. urinary tract infections, upper respiratory tract infections).
- •3. Clinically significant abnormal values for hematology, clinical chemistry or urinalysis, physical examination, vital signs or 12-lead electrocardiogram (ECG) at screening as deemed appropriate by the investigator
- •4. Pregnant or breast-feeding females or females planning a pregnancy during the study period.
- •5. Regular use of any prescription or nonprescription medication except contraceptives within the month preceding the baseline visit.
- •6. Regular use of ”probiotic” supplements.
- •7. Treatment with antimicrobial agents within the 3 months preceding the study.
- •8. History of, or a reason to believe a subject has a history of drug or alcohol abuse within the past 5 years.
- •9. Positive test for drugs of abuse at screening.
- •10. History of clinically significant allergies, requiring acute or chronic treatment (except seasonal allergic rhinitis)
- •11. Known allergy to the study drugs and any of the excipients of the formulation or any related substances.
- •12. Donated blood or blood products or had substantial loss of blood (more than 500 ml) within 1 month before baseline. Intention to donate blood or blood products during the treatment period or within 1 month after completion of the treatment period.
- •13. Positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies
- •14. Participation in any other clinical trials during the preceding 3 months.
- •15. Preplanned surgery or procedures that would interfere with the conduct of the study
- •16. Employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究者
相似试验
已完成
4 期
Examining whether any interactions occur between the antibiotic Ciprofloxacin and the antimalarial treatment Chloroquine/ProguanilPharmacokineticsISRCTN20647977Defence Science and Technology Laboratory (Dstl)16
进行中（未招募）
1 期
Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil ProphylaxisChloroquine/proguanil is used for malaria chemoprophylaxis in areas where chloroquine-resistant Plasmodium falciparum malaria is prevalent, except in regions of Africa where chloroquine/proguanil is no longer effective. Ciprofloxacin is a fluoroquinolone antibiotic used to treat a wide variety of infections, such as traveller`s diarrhoea. Only healthy subjects will be treated in this study.EUCTR2005-004905-27-GBDstl16
尚未招募
2 期
sing oral broad-spectrum antibiotics as an adjuvant therapy in conservative management of lumbar disc hernia; a clinical trialumbar disc herniaLumbar disc herniaNeurological - Other neurological disordersMusculoskeletal - Other muscular and skeletal disordersAnaesthesiology - Pain managementACTRN12613001074785Daniel F Fouladi90
进行中（未招募）
不适用
The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.Pharmacokinetics and pharmacodynamics, healthy volunteer trialEUCTR2008-007647-14-FITurku University Hospital12
已完成
不适用
Impact of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci among healthy volunteers: a randomised, double-blind, placebo-controlled trialISRCTN26642689Abbott Pharmaceuticals (Belgium)203